The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

Levi Strauss & Co.’s (LEVI) shares plunged 7.7% after reporting third-quarter fiscal 2024 net revenues of $1,517 million, missing the Zacks Consensus Estimate of $1,552 million. Shares of ...

S hares of Hims & Hers (NYSE: HIMS) fell as much as 15% on Thursday after news that Eli Lilly's (NYSE: LLY) GLP-1 drug was taken off the shortage list by the FDA. This could impac ...

The company has been doing incredibly well, and revenue as well as profits have skyrocketed in recent quarters. Shares of ...